2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-167960
    BrAc-Galactose-Sar-N-Me-alanine-DM1
    BrAc-Galactose-Sar-N-Me-alanine-DM1 (compound 11) is a drug-linker conjugate for ADC, which can be conjugated with the anti-TM4SF1 antibody (e.g., AGX-A07 (HY-P991187) for the synthesis of ADC.
    BrAc-Galactose-Sar-N-Me-alanine-DM1
  • HY-177109
    BL20-MMAE
    BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE (HY-15162) via a BL20 linker.
    BL20-MMAE
  • HY-153642
    MMAE-PAB(p-glucuronide)-PEG3-aminooxy
    MMAE-PAB(p-glucuronide)-PEG3-aminooxy is a compound with potential drug delivery.
    MMAE-PAB(p-glucuronide)-PEG3-aminooxy
  • HY-139909
    CL2E-SN38
    CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.
    CL2E-SN38
  • HY-185494
    Mal-Val-Lys-PAB-CBI-PBD dimer
    Mal-Val-Lys-PAB-CBI-PBD dimer is a Drug-Linker Conjugates for ADC. Mal-Val-Lys-PAB-CBI-PBD dimer consists of the ADC Cytotoxin CBI-PBD dimer and a linker Mal-Val-Lys-PAB. Mal-Val-Lys-PAB-CBI-PBD dimer exhibits alkylating activity at A-T-rich DNA minor groove adenine residues, disrupting DNA integrity. Mal-Val-Lys-PAB-CBI-PBD dimer induces cancer cell growth inhibition and cellular death. Mal-Val-Lys-PAB-CBI-PBD dimer can be used for the research of cancer.
    Mal-Val-Lys-PAB-CBI-PBD dimer
  • HY-160247
    Boc-Lys-PEG8-N-bis(D-glucose)
    Boc-Lys-PEG8-N-bis(D-glucose) (compound 89-5) is a drug linker that can be used in the synthesis of antibody-drug conjugates (ADCs) extracted from patent WO2023280227A2.
    Boc-Lys-PEG8-N-bis(D-glucose)
  • HY-128910
    MC-VC(S)-PABQ-Tubulysin M
    MC-VC(S)-PABQ-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-VC(S)- PABQ (an ADC linker) is connected. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors.
    MC-VC(S)-PABQ-Tubulysin M
  • HY-160143
    G3-VC-PAB-DMEA-Duocarmycin DM
    G3-VC-PAB-DMEA-Duocarmycin DM (Compound LD-1) is a duocarmycin-based linker molecule that can be used for ADC preparation..
    G3-VC-PAB-DMEA-Duocarmycin DM
  • HY-181058
    Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC
    Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC is a drug-linker conjugate, with Cyclopamine (HY-17024) as its drug moiety. Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC itself exhibits no significant anti-tumor activity. Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC can be used for the synthesis of ADC molecules.
    Cyclopamine-COO-2-ethoxy-1,3-benzodioxole-O-C-Triazole-C5-AC
  • HY-182972
    Mal-PEG4-NPV-PABC-DMEDA-tofacitinib
    Mal-PEG4-NPV-PABC-DMEDA-tofacitinib is a conjugate of a toxin and a linker, consisting of the JAK inhibitor Tofacitinib (HY-40354) and the linker Mal-PEG4-NPV-PABC-DMEDA (HY-182977). Mal-PEG4-NPV-PABC-DMEDA-tofacitinib can be used for the synthesis of ADC molecules.
    Mal-PEG4-NPV-PABC-DMEDA-tofacitinib
  • HY-171509
    Mal-N(Me)-C6-N(Me)-PNU-159682
    Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27), an agent-linker conjugate for ADC, consists the ADC linker Mal-N(Me)-C6-N(Me) and a potent ADC cytotoxin PNU-159682. Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) selectively delivers the payload to CD46-expressing cells, where the linker is cleaved by cathepsin B to release PNU-159682, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 shows durable tumor regression in xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
    Mal-N(Me)-C6-N(Me)-PNU-159682
  • HY-177687
    N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-153976
    Fmoc-Gly3-VC-PAB-MMAE
    Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker.
    Fmoc-Gly3-VC-PAB-MMAE
  • HY-P11316
    DBCO-tag peptide P1
    DBCO-tag peptide P1 is a cysteine-containing peptide tag. DBCO-tag peptide P1 selectively reacts with dibenzocyclooctyne (DBCO) to yield stable dibenzocyclooctenyl thioethers. DBCO-tag peptide P1 enables site-selective mEGFP labeling and antibody (such as Trastuzumab (HY-P9907)) labelling without impairing the protein binding function. DBCO-tag peptide P1 can be used for ADC synthesis and mEGFP labeling research.
    DBCO-tag peptide P1
  • HY-175614
    RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide
    RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide is a drug-linker conjugate for ADC. RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide consists of a GPX4 inhibitor and ferroptosis inducer (RSL3-NH2) (HY-175615) and a linker (H-Ala-Val-OH) (HY-P4955). RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide can be used for synthesis of ADCs.
    RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide
  • HY-158137A
    Val-Cit-PAB-DEA-Dxd TFA
    		99.11%
    Val-Cit-PAB-DEA-Dxd (Compound 81) TFA is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (HY-13631D). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis.
    Val-Cit-PAB-DEA-Dxd TFA
  • HY-158351
    Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag
    Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag is a drug-linker conjugate for ADC.
    Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag
  • HY-183254
    MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2CO-homocamptothecin analog
    MC-Gly-Gly-Phe-Gly-NH-CH₂-O-CH₂CO-homocamptothecin analog is a linker-payload conjugate, which can be used for the synthesis of ADCs.
    MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2CO-homocamptothecin analog
  • HY-185397
    2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan
    2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan is a Drug-linker conjugates for ADC consisting of the ADC Cytotoxin Exatecan (HY-13631) and a linker. 2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan can be used for synthesis of ADCs.
    2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan
  • HY-177682
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.